Location Framingham, Massachusetts, United States Regions Greater Boston Area, East Coast, New England Gender Male
LinkedIn View on LinkedIn
Mark Versavel joined Viepage as Co Founder in 2014. Dr. Versavel has 25 years of clinical development experience in neurology and psychiatry indications across the areas of clinical pharmacology, early and late phase clinical trials, as well as NDA approval and support of marketed products. He has made major contributions to the development of a
wide range of therapeutics which offered innovations in the fields of neurology and psychiatry. At Bayer AG, he played leadership roles in the development of metrifonate in Alzheimer’s disease, new formulations for nimodipine in subarrachnoidal haemorrhage, and controlled release formulations for ipsapirone in anxiety. At Schering AG, he was the core clinician for the Phase 2 development of an AMPA antagonist in stroke and the evaluation of betaferon in multiple sclerosis. At Pfizer, he was responsible for the Phase 3 international development of pregabalin (Lyrica®) in neuropathic pain and fibromyalgia, and for pediatric studies with ziprasidone (Geodon®) in schizophrenia and bipolar disorder. At Sunovion (previously Sepracor), he led the Phase 3 and NDA submission of eslicarbazepine acetate (Aptiom®) in epilepsy and provided medical affairs direction for eszopiclone (Lunesta®) in insomnia.
